|dc.creator||Chen B.-B.;Chao-Yu Hsu;Yu C.-W.;Liang P.-C.;Hsu C.;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.||-|
|dc.description.abstract||Objectives: To correlate early changes in the parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) within 1?week of systemic therapy with overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC). Methods: Eighty-nine patients with advanced HCC underwent DCE-MRI before and within 1?week following systemic therapy. The relative changes of six DCE-MRI parameters (Peak, Slope, AUC, Ktrans, Kep and Ve) of the tumours were correlated with OS using the Kaplan–Meier model and the double-sided log-rank test. Results: All patients died and the median survival was 174?days. Among the six DCE-MRI parameters, reductions in Peak, AUC, and Ktrans, were significantly correlated with one another. In addition, patients with a high Peak reduction following treatment had longer OS (P = 0.023) compared with those with a low Peak reduction. In multivariate analysis, a high Peak reduction was an independent favourable prognostic factor in all patients [hazard ratio (HR), 0.622; P = 0.038] after controlling for age, sex, treatment methods, tumour size and stage, and Eastern Cooperative Oncology Group performance status. Conclusions: Early perfusion changes within 1?week following systemic therapy measured by DCE-MRI may aid in the prediction of the clinical outcome in patients with advanced HCC. Key points: ? DCE-MRI is helpful to evaluate perfusion changes of HCC after systemic treatment. ? Early perfusion changes within 1?week after treatment may predict overall survival. ? High Peak reduction was an independent favourable prognostic factor after systemic treatment. ? 2016, European Society of Radiology.||-|
|dc.subject.other||placebo; sorafenib; UFT; vandetanib; contrast medium; adult; advanced cancer; aged; antiangiogenic activity; area under the curve; Article; cancer chemotherapy; cancer patient; cancer prognosis; cancer survival; clinical outcome; controlled study; dynamic contrast-enhanced magnetic resonance imaging; fatality; female; human; image analysis; Kaplan Meier method; liver cell carcinoma; major clinical study; male; overall survival; perfusion; priority journal; retrospective study; systemic therapy; cancer staging; disease exacerbation; follow up; liver cell carcinoma; liver circulation; liver tumor; magnetic resonance angiography; middle aged; multimodality cancer therapy; physiology; predictive value; prevalence; procedures; survival rate; Taiwan; time factor; trends; vascularization; very elderly; young adult; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Combined Modality Therapy; Contrast Media; Disease Progression; Female; Follow-Up Studies; Humans; Liver Circulation; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prevalence; Survival Rate; Taiwan; Time Factors; Young Adult||-|
|dc.title||Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma||en_US|
|crisitem.author.parentorg||College of Medicine||-|
|crisitem.author.parentorg||National Taiwan University Hospital||-|
|Appears in Collections:||醫學院附設醫院 (臺大醫院)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.